Merck Exceeds Q1 Sales Estimates on Keytruda Performance
Merck beat quarterly sales estimates as Keytruda revenue rose to $8 billion. The firm raised its 2026 profit forecast despite costs from recent acquisitions.
Xurve View
Insights:
Xurve View
MERCK & CO. INC. reported first-quarter revenue rose 5% to $16.3 billion, beating estimates of $15.8 billion. Strong demand for cancer drug Keytruda offset a $3.62-per-share charge from the Cidara Therapeutics acquisition. Investors are weighing Merck's ability to diversify revenue before Keytruda loses patent protection later this decade.
